3,4-二氟苯亚磺酸钠 | 114336-38-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-二氟苯亚磺酸钠
• 英文名称: sodium 3,4-difluorobenzenesulfinate
• 英文别名: 3,4-Difluorobenzenesulfinic acid sodium salt；sodium;3,4-difluorobenzenesulfinate
• CAS: 114336-38-8
• 化学式: C₆H₃F₂O₂S*Na
• 分子量: 200.141
• InChiKey: QSXOZTMYAQJHTR-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.79
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,4-二氟苯亚磺酸钠 在 四(三苯基膦)钯 、 potassium carbonate 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 3-((3,4-difluorophenyl)sulfonyl)-7-fluoro-4-(4-fluorophenyl)quinoline
  参考文献：
  名称：

  Discovery and Preclinical Characterization of 3-((4-(4-Chlorophenyl)-7-fluoroquinoline-3-yl)sulfonyl)benzonitrile, a Novel Non-acetylenic Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator for Psychiatric Indications

  摘要：

  Negative allosteric modulators (NAM) of metabotropic glutamate receptor 5 (mGluR5) have been implicated as a potential pharmacotherapy for a number of psychiatric diseases, including anxiety and depression. Most of the mGluR5 NAM clinical candidates can be characterized by the central acetylenic moiety that connects the terminal pharmacophores. Identification of a sulfoquinoline hit via high throughput screening (HTS) followed by optimization provided a 4-phenyl-3-aryl-sulfoquinoline lead compound with the minimal pharmacophore. Optimization of the core and aryl appendages was performed by scanning and matrix libraries synthesized by the multiple parallel synthesis approach. Biological evaluation of matrix libraries provided a number of potent, metabolically stable, and in vivo active compounds. One of these compounds, 25 showed high efficacy and safety in preclinical in vivo models; this allowed its nomination as a novel, nonacetylenic mGluR5 NAM clinical candidate. Compound 25 was advanced to first-in-man trials for the treatment of psychiatric conditions.

  DOI：

  10.1021/acs.jmedchem.6b01858
• 作为产物：
  描述：

  3,4-二氟苯-1-磺酰氯 在 碳酸氢钠 、 sodium sulfite 作用下， 以 水 为溶剂， 反应 3.0h， 生成 3,4-二氟苯亚磺酸钠
  参考文献：
  名称：

  钯亚锡与二锡烷的钯催化脱硫偶联反应合成芳基锡烷

  摘要：

  实现了新颖的钯催化的芳基亚磺酸钠与六烷基二锡烷的脱硫交叉偶联反应，从而能够以中等至优异的产率轻松合成官能化的芳基锡烷。克级合成和串联斯蒂勒偶联反应的成功实施证明了该方法在有机合成中的潜在应用。

  DOI：

  10.1016/j.tetlet.2018.09.065

文献信息

• Synthesis of <i>N</i>-arylsulfonamides through a Pd-catalyzed reduction coupling reaction of nitroarenes with sodium arylsulfinates
  作者：Bo Yang、Chang Lian、Guanglu Yue、Danyang Liu、Liyan Wei、Yi Ding、Xiancai Zheng、Kui Lu、Di Qiu、Xia Zhao

  DOI：10.1039/c8ob02226g

  日期：——

  A novel one-step direct reductive coupling reaction between nitroarenes and sodium arylsulfinates was realized in the presence of an inexpensive Pd/C catalyst. In this procedure, readily available nitroarenes are employed as the nitrogen sources, and sodium arylsulfinates serve as both coupling partners and reductants. The method features high efficiency by using cheap Pd/C with low catalyst loading

  在廉价的Pd / C催化剂的存在下，实现了硝基芳烃与芳基亚磺酸钠之间新颖的一步式直接还原偶联反应。在该方法中，将易得的硝基芳烃用作氮源，而芳基次磺酸钠既用作偶联配偶体又用作还原剂。该方法的特点是在不添加任何其他还原剂或配体的情况下，通过使用廉价的Pd / C，低催化剂负载量和良好的官能团耐受性来实现高效率。这种简便而温和的合成方法能够从容易获得的底物中高效合成官能化的N-芳基磺酰胺。
• Oxidative Sulfonylation of Hydrazones Enabled by Synergistic Copper/Silver Catalysis
  作者：Jun Xu、Chao Shen、Xian Qin、Jie Wu、Pengfei Zhang、Xiaogang Liu

  DOI：10.1021/acs.joc.0c02249

  日期：2021.3.5

  A copper/silver-cocatalyzed protocol for oxidative sulfonylation of hydrazones is demonstrated. A wide range of β-ketosulfones and N-acylsulfonamides are directly synthesized in moderate to good yields. Our work provides a viable method for scalable preparation of β-ketosulfone derivatives that have found wide applications in the pharmaceutical industry.

  证明了铜/银共催化的sulf的氧化磺酰化方案。可以以中等到良好的产率直接合成各种各样的β-酮砜和N-酰基磺酰胺。我们的工作为在制药工业中发现了广泛应用的β-酮砜衍生物的可扩展制备提供了一种可行的方法。
• Synthesis of arylstannanes by palladium-catalyzed desulfitative coupling reaction of sodium arylsulfinates with distannanes
  作者：Chang Lian、Guanglu Yue、Haonan Zhang、Liyan Wei、Danyang Liu、Sichen Liu、Huayi Fang、Di Qiu

  DOI：10.1016/j.tetlet.2018.09.065

  日期：2018.11

  A novel Pd-catalyzed desulfitative cross-coupling reaction of sodium arylsulfinates with hexaalkyl distannanes is realized, allowing the facile synthesis of functionalized arylstannanes with moderate to excellent yields. The successful implement of gram-scale synthesis and tandem Stille coupling reaction demonstrates the potential applications of this method in organic synthesis.

  实现了新颖的钯催化的芳基亚磺酸钠与六烷基二锡烷的脱硫交叉偶联反应，从而能够以中等至优异的产率轻松合成官能化的芳基锡烷。克级合成和串联斯蒂勒偶联反应的成功实施证明了该方法在有机合成中的潜在应用。
• Discovery of 4-amino-3-arylsulfoquinolines, a novel non-acetylenic chemotype of metabotropic glutamate 5 (mGlu 5 ) receptor negative allosteric modulators
  作者：János Galambos、Attila Bielik、Gábor Wágner、György Domány、János Kóti、Zoltán Béni、Áron Szigetvári、Zsuzsanna Sánta、Zoltán Orgován、Amrita Bobok、Béla Kiss、Mónika L. Mikó-Bakk、Mónika Vastag、Katalin Sághy、Mikhail Krasavin、Krisztina Gál、István Greiner、Zsolt Szombathelyi、György M. Keserű

  DOI：10.1016/j.ejmech.2017.03.071

  日期：2017.6

  optimized 4-methyl-piperidinyl-sulfoquinolines, however, were still insufficient for robust in vivo efficacy. Finally, introducing 4-hydoxymethyl-piperidinyl substituent to region I resulted in new sulfoquinolines with greatly improved solubility and reasonable affinity coupled with affordable metabolic stability. The most promising analogues (24 and 25) showed high blood levels and demonstrated significant

  代谢型谷氨酸受体5（mGlu5）的负变构调节剂在许多不同的中枢神经系统疾病（包括焦虑症和抑郁症）的动物模型中均显示出功效。实际上，到达临床的所有化合物都属于具有连接（杂）环部分的炔属接头的相同化学型。在寻找新的化学型时，我们通过筛选公司复合甲板确定了吗啉代-磺基喹啉衍生物（1）。命中率高的HTS对mGlu5受体表现出合理的亲和力和选择性，但是其较差的代谢稳定性阻碍了其体内测试。在化学程序中，我们旨在探究命中的三个区域，以改善亲和力，理化性质和代谢稳定性。4位（区域I）上不同胺的系统变化导致鉴定出4-甲基-哌啶基类似物。通过平行合成绘制了喹啉核心（II区）和苯磺酰基部分（III区）的取代基。对约270种衍生物的吗啉代和4-甲基-哌啶基-磺基喹啉文库的评估显示，区域II和III中具有有益的取代基组合。然而，优化的4-甲基-哌啶基-磺基喹啉的血药浓度仍不足以实现强大的体内功效。最后，将4-羟甲基
• Compounds - 945
  申请人：PIKE Kurt Gordon

  公开号：US20090018134A1

  公开（公告）日：2009-01-15

  A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.

  公式（I）的化合物或其药用盐，其制备方法，含有它们的药物组合物以及它们在治疗中的用途，例如在治疗增殖性疾病如癌症，特别是由mTOR激酶和/或一个或多个PI3K酶介导的疾病。